RecruitingNCT01353547

Genes and Environment in Multiple Sclerosis

Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility

Sponsor

Columbia University

Enrollment

5,000 participants

Start Date

Oct 1, 2017

Study Type

OBSERVATIONAL

Conditions

Multiple Sclerosis

Summary

The purpose of the research study is to identify the genetic, environmental and immune profiles that may increase a person's risk of developing multiple sclerosis (MS). While MS is not a disease caused by a single variation in genetic material (DNA), a single environmental factor, or a single malfunction in immune cells, there are genetic alterations, environmental exposures and immunologic factors that make the development of MS more likely. Obtaining information about who is at risk for MS will be beneficial in the future if the investigators can identify effective ways to prevent or slow down the progression of this disease.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study investigates how genes and environmental exposures interact to influence the risk of developing multiple sclerosis (MS), by studying family members of MS patients, people who have used certain anti-inflammatory drugs, and patients being evaluated for possible MS. **You may be eligible if...** - You are a first-degree relative (parent, sibling, or child) of someone diagnosed with MS - You have been treated with anti-TNF drugs (like Humira, Enbrel, or Remicade) for conditions such as Crohn's disease, psoriasis, or rheumatoid arthritis - You have been referred to a specialist for a first evaluation of new neurological symptoms but do not yet have an MS diagnosis - You live in the United States **You may NOT be eligible if...** - You do not meet any of the above inclusion criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(5)

National Institute of Neurological Disorders and Stroke

Bethesda, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Columbia University Irving Center

New York, New York, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01353547

Related Trials

Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?

NCT053577811 location

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

NCT027842101 location

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

NCT000012481 location

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT058494671 location

Blood Flow Restriction for Upper Limb Rehabilitation in People With Multiple Sclerosis. A Randomized Controlled Trial (BFRT-EM)

NCT067952301 location